Am. J. Respir. Crit. Care Med., Volume 164, Number 2, July 2001, 302-306

Effect of Aerosolized Uridine 5'-Triphosphate on Mucociliary Clearance in Mild Chronic Bronchitis

WILLIAM D. BENNETT, KIRBY L. ZEMAN, CARLA FOY, CHRISTY L. SHAFFER, FRED L. JOHNSON, JEFF A. REGNIS, ARUNA SANNUTI, and JANA JOHNSON

Division of Pulmonary Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; and Inspire Pharmaceuticals, Inc., Durham, North Carolina

Previous studies show that uridine 5'-triphosphate (UTP), a P2Y₂ receptor agonist, is effective at acutely enhancing mucociliary clearance in healthy, nonsmoking adults. UTP solution for inhalation is being developed by Inspire Pharmaceuticals under the compound number INS316. In a double-blind, randomized, crossover, placebo-controlled study we tested the single-dose effect of UTP in chronic smokers with mild chronic bronchitis (n = 15) by measuring the clearance of ^99mTc-Fe₂O₃ particles (4.0 µm mass median aerodynamic diameter [MMAD]) after inhalation of nebulized placebo (0.9% saline) and two doses of UTP (20 and 100 mg in the nebulizer). On each study day, gamma camera scanning was performed over a 2-h period. After an initial deposition scan, subjects inhaled placebo or UTP during the first 20 min of scanning. Analysis of whole lung clearance showed that the retention-time curves for each day were biphasic and that the earliest break point in the average curves occurred at 50 min. Mean particle clearance rate (Clr in %/min) through 50 min for placebo treatment was Clr = 0.65 ± 0.27 whereas treatment with UTP showed Clr significantly increased to 0.95 ± 0.48 and 0.93 ± 0.44 for the 20-mg and 100-mg dose respectively, p < 0.005 for both as compared with placebo. These data show that mucociliary clearance associated with mild chronic bronchitis is acutely improved with minimal doses of aerosolized UTP, presumably because of its stimulation of ciliary beating and hydration of airway secretions.

Keywords: uridine 5'-triphosphate; mucus clearance; safety

This article has been cited by other articles:

				R. R. Deterding, L. M. LaVange, J. M. Engels, D. W. Mathews, S. J. Coquillette, A. S. Brody, S. P. Millard, B. W. Ramsey, and for the Cystic Fibrosis Therapeutics Development N Phase 2 Randomized Safety and Efficacy Trial of Nebulized Denufosol Tetrasodium in Cystic Fibrosis Am. J. Respir. Crit. Care Med., August 15, 2007; 176(4): 362 - 369. [Abstract] [Full Text] [PDF]

				R.C. Boucher New concepts of the pathogenesis of cystic fibrosis lung disease Eur. Respir. J., January 1, 2004; 23(1): 146 - 158. [Abstract] [Full Text] [PDF]

				F. L. Johnson, J. F. Donohue, and C. L. Shaffer Improved Sputum Expectoration Following a Single Dose of INS316 in Patients With Chronic Bronchitis Chest, December 1, 2002; 122(6): 2021 - 2029. [Abstract] [Full Text] [PDF]

				D. J. Kellerman P2Y2 Receptor Agonists* : A New Class of Medication Targeted at Improved Mucociliary Clearance Chest, May 1, 2002; 121 (2009): 201S - 205S. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2001 Am. J. Respir. Crit. Care Med., March 1, 2002; 165(5): 642 - 662. [Full Text] [PDF]